Professor | Qi Tang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Qi Tang
Contact Information	qitang@njmu.edu.cn
Language ability	Chinese, English
Province	Jiangsu

Upload Avatar (500 x 500)

Name

Qi Tang

Contact Information

qitang@njmu.edu.cn

Language ability

Chinese, English

Province

Jiangsu

University/Lab Affiliation and Title	Nanjing Medical University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2007.4-present: Assistant Researcher, Associate Researcher at Nanjing Medical University, National Health Commission Key Laboratory of Antibody Technology 2011.8-2013.3: Visiting Scholar at University of Texas Health Science Center 2010.9-2018.7: PhD in Pathology and Pathophysiology, Nanjing Medical University 2004.9-2007.7: Master's in Pathology and Pathophysiology, Nanjing Medical University 1998.9-2003.7: Bachelor's in Clinical Medicine, Hebei Medical University
Work Experience	2007.4-present - Nanjing Medical University - Assistant Researcher, Associate Researcher 2011.8-2013.3 - University of Texas Health Science Center - Visiting Scholar
Awards	2021: Third Prize, Jiangsu Higher Education Science and Technology Research Achievement Award, Jiangsu Provincial Department of Education 2020: Second Prize, Military Science and Technology Progress Award, Central Military Science and Technology Commission 2019: Second Prize, Jiangsu Medical New Technology Introduction Award, Jiangsu Provincial Health Commission 2017: Second Prize, Military Science and Technology Progress Award, Central Military Science and Technology Commission 2016: First Prize, Jiangsu Preventive Medicine Science and Technology Award, Jiangsu Preventive Medicine Association 2011: Third Prize, Jiangsu Medical Science and Technology Award, Jiangsu Medical Association

University/Lab Affiliation and Title

Nanjing Medical University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2007.4-present: Assistant Researcher, Associate Researcher at Nanjing Medical University, National Health Commission Key Laboratory of Antibody Technology
2011.8-2013.3: Visiting Scholar at University of Texas Health Science Center
2010.9-2018.7: PhD in Pathology and Pathophysiology, Nanjing Medical University
2004.9-2007.7: Master's in Pathology and Pathophysiology, Nanjing Medical University
1998.9-2003.7: Bachelor's in Clinical Medicine, Hebei Medical University

Work Experience

2007.4-present - Nanjing Medical University - Assistant Researcher, Associate Researcher
2011.8-2013.3 - University of Texas Health Science Center - Visiting Scholar

Awards

2021: Third Prize, Jiangsu Higher Education Science and Technology Research Achievement Award, Jiangsu Provincial Department of Education
2020: Second Prize, Military Science and Technology Progress Award, Central Military Science and Technology Commission
2019: Second Prize, Jiangsu Medical New Technology Introduction Award, Jiangsu Provincial Health Commission
2017: Second Prize, Military Science and Technology Progress Award, Central Military Science and Technology Commission
2016: First Prize, Jiangsu Preventive Medicine Science and Technology Award, Jiangsu Preventive Medicine Association
2011: Third Prize, Jiangsu Medical Science and Technology Award, Jiangsu Medical Association

Areas of Focus	Single B-cell sequencing and fully human antibody preparation technology Development of anti-tumor therapeutic antibodies and related drugs Tumor immunotherapy and translational research
Publications	Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma., Yan Peng, Wenqing Zhang, Yufeng Chen, Louqian Zhang, Hongyu Shen, Zheyue Wang, Shuning Tian, Xiaohui Yang, Daixun Cui, Yiting He, Xinxia Chang, Zhenqing Feng, Qi Tang, Yuan Mao, 2023 A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME., Xuejun Xiao, Yan Peng, Zheyue Wang, Louqian Zhang, Tingting Yang, Yangyang Sun, Yufeng Chen, Wenqing Zhang, Xinxia Chang, Wen Huang, Shuning Tian, Zhenqing Feng, Nabi Xinhua, Qi Tang, Yuan Mao, 2022 Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy., Haishi Qiao, Xingmei Chen, Qiming Wang, Junmei Zhang, Dechun Huang, Enping Chen, Hongliang Qian, Yinan Zhong, Qi Tang, Wei Chen, 2020 MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells., Yuan Mao, Weifei Fan, Hao Hu, Louqian Zhang, Jerod Michel, Yaqin Wu, Jun Wang, Lizhou Jia, Xiaojun Tang, Li X, Yan Chen, Jin Zhu, Zhenqing Feng, Lin Xu, Rong Yin, Qi Tang, 2019 Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine., Daniel C Freed, Qi Tang, Aimin Tang, Fengsheng Li, Xi He, Zhao Huang, Weixu Meng, Lin Xia, Adam C Finnefrock, Eberhard Durr, Amy S Espeseth, Danilo R Casimiro, Ningyan Zhang, John W Shiver, Dai Wang, Zhiqiang An, Tong-Ming Fu, 2013

Areas of Focus

Single B-cell sequencing and fully human antibody preparation technology
Development of anti-tumor therapeutic antibodies and related drugs
Tumor immunotherapy and translational research

Publications

Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma., Yan Peng, Wenqing Zhang, Yufeng Chen, Louqian Zhang, Hongyu Shen, Zheyue Wang, Shuning Tian, Xiaohui Yang, Daixun Cui, Yiting He, Xinxia Chang, Zhenqing Feng, Qi Tang, Yuan Mao, 2023
A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME., Xuejun Xiao, Yan Peng, Zheyue Wang, Louqian Zhang, Tingting Yang, Yangyang Sun, Yufeng Chen, Wenqing Zhang, Xinxia Chang, Wen Huang, Shuning Tian, Zhenqing Feng, Nabi Xinhua, Qi Tang, Yuan Mao, 2022
Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy., Haishi Qiao, Xingmei Chen, Qiming Wang, Junmei Zhang, Dechun Huang, Enping Chen, Hongliang Qian, Yinan Zhong, Qi Tang, Wei Chen, 2020
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells., Yuan Mao, Weifei Fan, Hao Hu, Louqian Zhang, Jerod Michel, Yaqin Wu, Jun Wang, Lizhou Jia, Xiaojun Tang, Li X, Yan Chen, Jin Zhu, Zhenqing Feng, Lin Xu, Rong Yin, Qi Tang, 2019
Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine., Daniel C Freed, Qi Tang, Aimin Tang, Fengsheng Li, Xi He, Zhao Huang, Weixu Meng, Lin Xia, Adam C Finnefrock, Eberhard Durr, Amy S Espeseth, Danilo R Casimiro, Ningyan Zhang, John W Shiver, Dai Wang, Zhiqiang An, Tong-Ming Fu, 2013

B-Cell Sequencing Antibody Preparation Technology Anti-Tumor Therapeutic Drugs Immunotherapy Translational

Xiaonan Wang - China Medical University

Hua Feng Zhang - University of Science and Technology of China

Zhenqing Feng - Nanjing Medical University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us